Investment
Features
FeesSafety
Academy
More
Pluang+

Compare National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares (NGG) vs Sana Biotechnology Inc (SANA) Price & Performance

National Grid Transco PLC National Grid PLC (NEW) American Depositary SharesTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares vs Sana Biotechnology Inc — how do they compare? National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares trades at $79.17 (market cap $78.99B), while Sana Biotechnology Inc trades at $2.33 (market cap $697.51M). The key difference: National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares is far larger — about 113.2× Sana Biotechnology Inc's market cap, and National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares pays a 4.13% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.

NGGSANA
Market Cap
$78.99B$697.51M
Volume
740,4022,763,583
Sector
UtilitiesHealth
52-Week High
$93.93$5.92
52-Week Low
$73.54$2.33
Enterprise Value
$137.22B$610.76M
Dividend Yield
4.13%—
Typical Hold Time
—24 Days

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares

National Grid (NGG) trades at $78.23, up 1.44% on the day, with a market cap of approximately $48.3 billion. The stock shows stable technicals near its consensus price target of $79.25. Fundamentally, it maintains strong profitability with an 18.32% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights institutional buying and a focus on grid innovation, including AI adoption.

Outlook is cautiously positive with upside to the high target of $85.50, supported by earnings momentum and strategic investments. Risks include high debt levels and regulatory pressures. Analyst consensus leans buy (55%), but hold ratings reflect concerns over capital intensity and macroeconomic sensitivity.

Sana Biotechnology Inc

SANA Biotechnology trades at $2.41, down 8.02% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company shows no revenue with substantial losses (-$244.17M net income in 2025) and negative cash flow, though analyst consensus remains strongly positive with 82% buy ratings. Recent investor conference presentations indicate active business development efforts.

The stock presents high-risk speculative potential with strong Wall Street support but faces fundamental challenges including no revenue generation and significant cash burn. Investment opportunity hinges on successful clinical developments, while risks include continued operational losses and potential dilution from financing activities.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NGG

No sentiment data available yet.

SANA
75% Buy25% Sell
Avg holding period · 24 Days

Top news

Latest headlines on both assets

About National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares

National Grid plc is a British utility company that owns and operates electricity and gas transmission networks in Great Britain, and through its US Regulated business, operates electricity and gas transmission and distribution networks serving customers in New York and Massachusetts. Its shares trade on the NYSE as American Depositary Shares under the ticker NGG.

Read more on NGG →

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA →